Table IV.
Patient characteristics
Patient and tumor characteristics for samples included in the validation set are shown.
ER, estrogen receptor α; PgR, progesterone receptor.
| Characteristics | Numbers | Median | Percent |
|---|---|---|---|
| Patients | 130 | 100 | |
| Age (years) | |||
| Primary surgery | 53.5 | ||
| Start first line | 56.5 | ||
| Menopausal status at start first line | |||
| Pre | 40 | 30.8 | |
| Post | 90 | 69.2 | |
| ER (fmol/mg protein) | 97 | ||
| PgR (fmol/mg protein) | 54.5 | ||
| Response | |||
| Clinical benefit: CR, PR, S.D. ≥ 6 months | 77 | 59.2 | |
| No clinical benefit: S.D. < 6 months, PD | 53 | 40.8 | |
| Dominant site of relapse | |||
| Local regional relapse | 15 | 11.5 | |
| Bone | 65 | 50.0 | |
| Other | 50 | 38.5 | |
| Disease-free interval (months) | |||
| ≤12 | 16 | 12.3 | |
| 12–36 | 59 | 45.4 | |
| ≥36 | 55 | 42.3 | |
| Nodal status | |||
| N0 | 62 | 47.7 | |
| N1–3 | 30 | 23.1 | |
| N > 3 | 34 | 26.2 | |
| Unknown | 4 | 3.1 | |
| Tumor size | |||
| ≤2 cm | 67 | 51.5 | |
| >2 cm | 63 | 48.5 | |
| Tumor grade | |||
| Poor | 46 | 35.4 | |
| Unknown | 52 | 40.0 | |
| Good/moderate | 32 | 24.6 |